JNK suppression is essential for 17-Estradiol inhibits prostaglandin E2-Induced uPA and MMP-9 expressions and cell migration in human LoVo colon cancer cells

Journal of Biomedical Science

Volumn 18, Issue 1, 2011, Pages

  Hsu, Hsi Hsien ^a,b   Hu, Wei Syun ^c,d   Lin, Yueh Min ^e,f   Kuo, Wei Wen ^d   Chen, Li Mien ^g   Chen, Wei Kung ^h   Hwang, Jin Ming ^e   Tsai, Fuu Jen ^h   Liu, Chung Jung ⁱ   Huang, Chih Yang ^d,j  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^f JEN TEH JUNIOR COLLEGE OF MEDICINE   (Taiwan)

^g Taichung General Hospital   (Taiwan)

^h CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^j ASIA UNIVERSITY   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ESTRADIOL; FULVESTRANT; GELATINASE B; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDIN E2; QUINAZOLINE; STRESS ACTIVATED PROTEIN KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; SERPINE1 PROTEIN, HUMAN; STRESS ACTIVATED PROTEIN KINASE 1;

ADULT; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CELL MOTILITY; CELL STRAIN LOVO; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; CELL MOTION; COLON TUMOR; FEMALE; GENE EXPRESSION REGULATION; IMMUNOBLOTTING; MALE; METABOLISM; PATHOPHYSIOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; DINOPROSTONE; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; MALE; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MITOGEN-ACTIVATED PROTEIN KINASE 8; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE INHIBITOR OF METALLOPROTEINASES; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 80052027030     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-18-61     Document Type: Article

References (52)

1. Cancer statistics, 2005. Jemal A, Murray T, Ward E, et al. CA Cancer J Clin 2005 55 10 30 10.3322/canjclin.55.1.10 15661684 (Pubitemid 40310185)
2. Colon cancer overview. Greenwald P, Cancer 1992 70 1206 1215 10.1002/1097-0142(19920901)70:3+<1206::AID-CNCR2820701504>3.0.CO;2-J 1511368
3. Cancer statistics, 2002. Jemal A, Thomas A, Murray T, et al. CA Cancer J Clin 2002 52 23 47 10.3322/canjclin.52.1.23 11814064 (Pubitemid 34110469)
4. Cancer statistics, 2004. Jemal A, Tiwari RC, Murray T, et al. CA Cancer J Clin 2004 54 8 29 10.3322/canjclin.54.1.8 14974761 (Pubitemid 38443417)
5. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Liotta LA, Stetler-Stevenson WG, Cancer Res 1991 51 5054s 5059s 1884381
6. Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis. Yoon WH, Jung YJ, Kim TD, et al. Clin Cancer Res 2004 10 13 4517 4526 10.1158/1078-0432.CCR-04-0084 15240544 (Pubitemid 38878896)
7. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Coussens LM, Fingleton B, Matrisian LM, Science 2002 295 5564 2387 2392 10.1126/science.1067100 11923519 (Pubitemid 34270240)
8. Membrane associated matrix metalloproteinases in metastasis. Ellerbroek SM, Stack MS, Bioessays 1999 21 11 940 949 10.1002/(SICI)1521-1878(199911)21: 11<940::AID-BIES6>3.0.CO;2-J 10517867 (Pubitemid 29530603)
9. The role of gelatinases in colorectal cancer progression and metastasis. Mook OR, Frederiks WM, Van Noorden CJ, Biochim Biophys Acta 2004 1705 2 69 89 15588763 (Pubitemid 39592897)
10. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Gomez DE, Alonso DF, Yoshiji H, et al. Eur J Cell Biol 1997 74 2 111 122 9352216 (Pubitemid 27455388)
11. Plasmin/plasminogen system in colorectal cancer. Berger DH, World J Surg 2002 26 7 767 771 10.1007/s00268-002-4050-8 11965442 (Pubitemid 36920315)
12. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. Seetoo DQ, Crowe PJ, Russell PJ, et al. J Surg Oncol 2003 82 3 184 193 10.1002/jso.10210 12619063 (Pubitemid 36278267)
13. Diet, gender, and colorectal neoplasia. Jacobs ET, Thompson PA, Martinez ME, J Clin Gastroenterol 2007 41 8 731 746 10.1097/MCG.0b013e3180338e56 17700421 (Pubitemid 47267759)
14. Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses. Katzenellenbogen JA, Katzenellenbogen BS, Chem Biol 1996 3 7 529 536 10.1016/S1074-5521(96)90143-X 8807884 (Pubitemid 26324165)
15. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Campbell-Thompson M, Lynch IJ, Bhardwaj B, Cancer Res 2001 61 2 632 640 11212261 (Pubitemid 32128626)
16. Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Gambacciani M, Monteleone P, Sacco A, et al. Best Pract Res Clin Endocrinol Metab 2003 17 1 139 147 10.1016/S1521-690X(02)00086-6 12763517
17. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Grodstein F, Martinez ME, Platz EA, et al. Ann Intern Med 1998 128 9 705 712 9556463 (Pubitemid 28204861)
18. Estrogen plus progestin and colorectal cancer in postmenopausal women. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. N Engl J Med 2004 350 10 991 1004 10.1056/NEJMoa032071 14999111 (Pubitemid 38269276)
19. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. Calle EE, Miracle-McMahill HL, Thun MJ, et al. J Natl Cancer Inst 1995 87 7 517 523 10.1093/jnci/87.7.517 7707438
20. 17beta-estradiol inhibits prostaglandin E2-induced COX-2 expressions and cell migration by suppressing Akt and ERK1/2 signaling pathways in human LoVo colon cancer cells. Lai TY, Chen LM, Lin JY, et al. Mol Cell Biochem 2010 342 1-2 63 70 10.1007/s11010-010-0469-7 20446020
21. Increased matrix metalloproteinase 2 concentration and transcript expression in advanced colorectal carcinomas. Chan CC, Menges M, Orzechowski HD, et al. Int J Colorectal Dis 2001 16 3 133 140 10.1007/s003840100287 11459286 (Pubitemid 32591162)
22. Activity and cellular origin of gelatinases in patients with colon and rectal carcinoma differential activity of matrix metalloproteinase-9. Roeb E, Dietrich CG, Winograd R, et al. Cancer 2001 92 10 2680 2691 10.1002/1097- 0142(20011115)92:10<2680::AID-CNCR1622>3.0.CO;2-7 11745204 (Pubitemid 33049453)
23. Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase. Collins HM, Morris TM, Watson SA, Br J Cancer 2001 84 12 1664 1670 10.1054/bjoc.2001.1831 11401321 (Pubitemid 32612499)
24. Distribution of gelatinase B (MMP-9) and type IV collagen in colorectal carcinoma. Jeziorska M, Haboubi NY, Schofield PF, et al. Int J Colorectal Dis 1994 9 3 141 148 10.1007/BF00290191 7814988 (Pubitemid 24247561)
25. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Zucker S, Vacirca J, Cancer Metastasis Rev 2004 23 1-2 101 117 15000152 (Pubitemid 38221598)
26. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. Baker EA, Leaper DJ, Eur J Cancer 2003 39 7 981 988 10.1016/S0959-8049(03)00065-0 12706368 (Pubitemid 36428631)
27. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression. Baker EA, Bergin FG, Leaper DJ, Mol Pathol 2000 53 6 307 312 10.1136/mp.53.6.307 11193049
28. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Li YY, McTiernan CF, Feldman AM, Cardiovasc Res 2000 46 2 214 224 10.1016/S0008- 6363(00)00003-1 10773225 (Pubitemid 30204593)
29. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Goldberg GI, Marmer BL, Grant GA, et al. Proc Natl Acad Sci USA 1989 86 21 8207 8211 10.1073/pnas.86.21.8207 2554304 (Pubitemid 19286028)
30. Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Bian J, Wang Y, Smith MR, et al. Carcinogenesis 1996 17 9 1805 1811 10.1093/carcin/17.9.1805 8824499 (Pubitemid 26325368)
31. AdTIMP-2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice. Li H, Lindenmeyer F, Grenet C, et al. Hum Gene Ther 2001 12 5 515 526 10.1089/104303401300042429 11268284 (Pubitemid 32511073)
32. Estrogen signaling multiple pathways to impact gene transcription. Marino M, Galluzzo P, Ascenzi P, Curr Genomics 2006 7 8 497 508 10.2174/ 138920206779315737 18369406 (Pubitemid 46068961)
33. Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation. Mao J, Xu Z, Fang Y, et al. Cancer Sci 2008 99 11 2120 2127 10.1111/j.1349-7006. 2008.00928.x 18823380
34. Heme oxygenase-1 inhibits the proliferation of pancreatic stellate cells by repression of the ERK1/2 pathway. Schwer CI, Guerrero AM, Humar M, et al. J Pharmacol Exp Ther 2008 327 3 863 871 10.1124/jpet.108.136549 18784349
35. Signaling pathway for TNF-alpha-induced MMP-9 expression: Mediation through p38 MAP kinase, and inhibition by anti-cancer molecule magnolol in human urinary bladder cancer 5637 cells. Lee SJ, Park SS, Lee US, et al. Int Immunopharmacol 2008 8 13-14 1821 1826 10.1016/j.intimp.2008.08.018 18801463
36. Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: possible mediation by decreased JNK/AP-1 signaling. Kwon GT, Cho HJ, Chung WY, et al. J Nutr Biochem 2009 20 9 663 676 10.1016/j.jnutbio.2008.06.005 18824345
37. Hepatocyte growth factor enhances proteolysis and invasiveness of human nasopharyngeal cancer cells through activation of PI3K and JNK. Zhou HY, Wan KF, Ip CK, et al. FEBS Lett 2008 582 23-24 3415 3422 10.1016/j.febslet.2008.09.004 18789327
38. Molecular mechanisms involved in chemoresistance in paediatric acute lymphoblastic leukaemia. Stankovic T, Marston E, Srp Arh Celok Lek 2008 136 3-4 187 192 10.2298/SARH0804187S 18720757
39. Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer. Mostafaie N, Kallay E, Sauerzapf E, et al. Mol Carcinog 2009 48 7 642 647 10.1002/mc.20510 19148895
40. Sex-specific differences in the expression levels of estrogen receptor subtypes in colorectal cancer. Nussler NC, Reinbacher K, Shanny N, et al. Gend Med 2008 5 3 209 217 10.1016/j.genm.2008.07.005 18727987
41. Loss of estrogen inactivation in colonic cancer. English MA, Kane KF, Cruickshank N, et al. J Clin Endocrinol Metab 1999 84 6 2080 2085 10.1210/jc.84.6.2080 10372714 (Pubitemid 30647037)
42. Estrogen, hormonal replacement therapy and cardiovascular disease. Yang XP, Reckelhoff JF, Curr Opin Nephrol Hypertens 2011 20 133 138 10.1097/MNH.0b013e3283431921 21178615
43. Akt mediates 17beta-estradiol and/or estrogen receptor-alpha inhibition of LPS-induced tumor necresis factor-alpha expression and myocardial cell apoptosis by suppressing the JNK1/2-NFkappaB pathway. Liu CJ, Lo JF, Kuo CH, et al. J Cell Mol Med 2009 13 9B 3655 3667 10.1111/j.1582-4934.2009.00669.x 20196785
44. Signaling by estrogens. Cheskis BJ, Greger JG, Nagpal S, et al. J Cell Physiol 2007 213 3 610 617 10.1002/jcp.21253 17886255 (Pubitemid 350058252)
45. Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. Razandi M, Alton G, Pedram A, et al. Mol Cell Biol 2003 23 5 1633 1646 10.1128/MCB.23.5. 1633-1646.2003 12588983 (Pubitemid 36246045)
46. Extranuclear steroid receptors: nature and actions. Hammes SR, Levin ER, Endocr Rev 2007 28 7 726 741 10.1210/er.2007-0022 17916740 (Pubitemid 350294293)
47. Proximal events in signaling by plasma membrane estrogen receptors. Razandi M, Pedram A, Park ST, et al. J Biol Chem 2003 278 4 2701 2712 10.1074/jbc.M205692200 12421825 (Pubitemid 36801351)
48. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. Chen Z, Yuhanna IS, Galcheva-Gargova Z, et al. J Clin Invest 1999 103 3 401 406 10.1172/JCI5347 9927501 (Pubitemid 29069990)
49. The protective effects of estrogen on the cardiovascular system. Mendelsohn ME, Karas RH, N Engl J Med 1999 340 1801 1811 10.1056/ NEJM199906103402306 10362825 (Pubitemid 29266405)
50. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. Kahlert S, Nuedling S, van Eickels M, et al. J Biol Chem 2000 275 18447 18453 10.1074/jbc.M910345199 10749889 (Pubitemid 30414803)
51. Expression of estrogen receptor beta in colon cancer progression. Castiglione F, Taddei A, Degl'Innocenti DR, et al. Diagn Mol Pathol 2008 17 4 231 236 10.1097/PDM.0b013e3181656d67 19034156
52. ERbeta expression in normal, adenomatous and carcinomatous tissues of patients with familial adenomatous polyposis. Barone M, Scavo MP, Papagni S, et al. Scand J Gastroenterol 2010 45 11 1320 1328 10.3109/00365521.2010.487915 20446826